Bevacizumab treatment for subfoveal choroidal neovascularization from causes other than age-related macular degeneration
Bevacizumab treatment for subfoveal choroidal neovascularization from causes other than age-related macular degeneration
复制标题
DOI：
10.1001/archopht.126.7.941
复制
发表时间：
2008-07-01
影响因子：
--
通讯作者：
Slakter, Jason S.
中科院分区：
文献类型：
--
作者：
Chang, Louis K.;Spaide, Richard F.;Slakter, Jason S.
目的：报告玻璃体内贝伐单抗（安维汀）治疗脉络膜新生血管（CNV）的原因以外的年龄相关性黄斑变性（AMD）的结果：方法：我们进行了一项回顾性分析的眼睛接受玻璃体内贝伐单抗，1.25毫克，在一个基于视网膜的视网膜实践的中心凹下非AMD CNV。如果出现持续性或复发性渗出体征，则重复玻璃体内贝伐珠单抗治疗。主要结果指标为视力（VA）。结果：该研究包括36例39眼继发于多灶性脉络膜炎（n = 12）、血管样条纹（n = 11）、近视变性（n = 10）、特发性疾病（n = 4）或其他疾病（n = 2）的中心凹下CNV患者。中位基线VA为20/60（logMAR，0.48）。平均随访时间为58.8周，每只眼平均注射次数为3.4次。3个月随访后，中位VA为20/30（logMAR，0.18）（P = .004 vs基线）。末次随访时，中位VA为20/40（logMAR，0.30）。与基线相比，这仍然是一种改善（P <0.02），但比3个月随访时更差（P <0.03）。基础诊断和VA变化之间没有相关性follow-up.Conclusion：尽管基础病因不同，但玻璃体内贝伐单抗治疗继发于非AMD原因的中心凹下CNV反应良好，相似。
Objective: To report the results of intravitreous bevacizumab (Avastin) treatment for choroidal neovascularization (CNV) from causes other than age-related macular degeneration (AMD).Methods: We performed a retrospective analysis of eyes that received intravitreous bevacizumab, 1.25 mg, for sub-foveal non-AMD CNV at a referral-based retinal practice. Repeated treatment with intravitreous bevacizumab occurred if there were signs of persistent or recurrent exudation. The main outcome measure was visual acuity (VA).Results: The study included 39 eyes of 36 patients with subfoveal CNV secondary to multifocal choroiditis (n = 12), angioid streaks (n = 11), myopic degeneration (n = 10), idiopathic disease (n = 4), or other disease (n = 2). The median baseline VA was 20/60 (logMAR, 0.48). The mean follow-up was 58.8 weeks, and the mean number of injections per eye was 3.4. After 3-month follow-up, the median VA was 20/30 (logMAR, 0.18) (P = .004 vs baseline). At last follow-up, the median VA was 20/40 (logMAR, 0.30). This remained an improvement compared with baseline (P < .02) but was worse than 3-month follow-up (P < .03). There was no correlation between underlying diagnosis and VA change during follow-up.Conclusion: Subfoveal CNV secondary to non-AMD causes treated with intravitreous bevacizumab responded favorably and similarly, despite varying underlying etiologies.